MX2021009670A - Tratamiento para el cancer. - Google Patents
Tratamiento para el cancer.Info
- Publication number
- MX2021009670A MX2021009670A MX2021009670A MX2021009670A MX2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A MX 2021009670 A MX2021009670 A MX 2021009670A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer treatment
- cancer
- treatment
- erdafitinib
- provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para el tratamiento del cáncer con erdafitinib en pacientes de alto riesgo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19156806 | 2019-02-12 | ||
EP19176575 | 2019-05-24 | ||
PCT/EP2020/053490 WO2020165181A1 (en) | 2019-02-12 | 2020-02-11 | Cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009670A true MX2021009670A (es) | 2021-09-08 |
Family
ID=69467563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009670A MX2021009670A (es) | 2019-02-12 | 2020-02-11 | Tratamiento para el cancer. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220168298A1 (es) |
EP (1) | EP3923942A1 (es) |
JP (1) | JP2022521173A (es) |
KR (1) | KR20210126654A (es) |
CN (1) | CN113423402A (es) |
AU (1) | AU2020223467A1 (es) |
BR (1) | BR112021015686A2 (es) |
CA (1) | CA3126959A1 (es) |
IL (1) | IL285466A (es) |
JO (1) | JOP20210216A1 (es) |
MA (1) | MA54932A (es) |
MX (1) | MX2021009670A (es) |
SG (1) | SG11202107850VA (es) |
TW (1) | TW202045173A (es) |
WO (1) | WO2020165181A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022125967A2 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
CN112957368A (zh) * | 2021-04-02 | 2021-06-15 | 南昌大学 | 一种司维拉姆的新用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017070708A1 (en) * | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
TWI798199B (zh) * | 2017-02-06 | 2023-04-11 | 比利時商健生藥品公司 | 癌症治療 |
JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2020
- 2020-02-11 JP JP2021547154A patent/JP2022521173A/ja active Pending
- 2020-02-11 SG SG11202107850VA patent/SG11202107850VA/en unknown
- 2020-02-11 WO PCT/EP2020/053490 patent/WO2020165181A1/en unknown
- 2020-02-11 KR KR1020217028671A patent/KR20210126654A/ko active Search and Examination
- 2020-02-11 MA MA054932A patent/MA54932A/fr unknown
- 2020-02-11 US US17/430,025 patent/US20220168298A1/en active Pending
- 2020-02-11 MX MX2021009670A patent/MX2021009670A/es unknown
- 2020-02-11 CN CN202080013784.5A patent/CN113423402A/zh active Pending
- 2020-02-11 CA CA3126959A patent/CA3126959A1/en active Pending
- 2020-02-11 BR BR112021015686-0A patent/BR112021015686A2/pt unknown
- 2020-02-11 JO JOP/2021/0216A patent/JOP20210216A1/ar unknown
- 2020-02-11 EP EP20703477.8A patent/EP3923942A1/en active Pending
- 2020-02-11 AU AU2020223467A patent/AU2020223467A1/en active Pending
- 2020-02-12 TW TW109104389A patent/TW202045173A/zh unknown
-
2021
- 2021-08-09 IL IL285466A patent/IL285466A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA54932A (fr) | 2021-12-22 |
SG11202107850VA (en) | 2021-08-30 |
JP2022521173A (ja) | 2022-04-06 |
AU2020223467A1 (en) | 2021-08-05 |
JOP20210216A1 (ar) | 2023-01-30 |
TW202045173A (zh) | 2020-12-16 |
US20220168298A1 (en) | 2022-06-02 |
BR112021015686A2 (pt) | 2021-10-26 |
KR20210126654A (ko) | 2021-10-20 |
CA3126959A1 (en) | 2020-08-20 |
CN113423402A (zh) | 2021-09-21 |
EP3923942A1 (en) | 2021-12-22 |
IL285466A (en) | 2021-09-30 |
WO2020165181A1 (en) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA193736S (en) | Skin massager | |
EP3867410A4 (en) | METHODS OF DETERMINING A TREATMENT FOR CANCER PATIENTS | |
WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
MX2022008868A (es) | Tratamiento del cancer con tg02. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
WO2018136617A3 (en) | Bacteria for treating cancer | |
AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
GB201903546D0 (en) | Cancer treatment | |
EA201991818A1 (ru) | Лечение рака | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
MX2020008195A (es) | Compuestos para el tratamiento del dolor. | |
EP4353320A3 (en) | Blood plasma and plasma fractions as therapy for tumor growth and progression | |
TN2019000211A1 (en) | Antitumoral compounds | |
ZA202206743B (en) | Therapy for the treatment of cancer | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
PH12020551080A1 (en) | Combination therapy for treating or preventing cancer | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
IL281845A (en) | Combined treatment for cancer | |
IL287652A (en) | Cancer treatment | |
IL281439A (en) | Combined treatment for blood cancer | |
IL284162A (en) | Integrated healing for cancer treatment | |
MX2021009670A (es) | Tratamiento para el cancer. | |
MX2017016346A (es) | Metodos de tratamiento con taselisib. | |
MX2020012964A (es) | Metodos para el tratamiento de cancer de vejiga. | |
MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. |